1. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate 
Ari Lindqvist, MDa, Eeva-Maija Karjalainen, MDa, Lauri A. Laitinen, MD, FRCPa, Tuomo Kava, MDb, Alan Altraja, MDc, Markku Pulkkinen, RPNd, Maija Halme, MDa, Annika Laitinen, MDc 
Journal of Allergy and Clinical Immunology 
Volume 112, Issue 1, Pages (July 2003)
DOI: /mai
Copyright © 2003 Mosby, Inc. Terms and Conditions

2. Fig. 1
Layout of the study. After a 2-week run-in, eligible patients were randomly assigned (visit 2) to one of the four treatment arms for 16 weeks. Patients returned to their individualized asthma treatment at visit 6 and ended the study 2 weeks later at visit 7.
Journal of Allergy and Clinical Immunology  , 23-28DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mean daytime symptom scores, daytime need for rescue medication, and morning peak flow (PEF) are presented as a green line for salmeterol group (SLM), a red line for fluticasone propionate group (FP), a yellow line for disodium cromoglycate group (DSCG), and a black line for placebo group (PL).
Journal of Allergy and Clinical Immunology  , 23-28DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions

4. Fig. 3
Number of EG2-positive cells in bronchial submucosa before and after 16 weeks' treatment with salmeterol (SLM) , fluticasone propionate (FP) , disodium cromoglycate (DSCG) , and placebo (PL) .
Journal of Allergy and Clinical Immunology  , 23-28DOI: ( /mai )
Copyright © 2003 Mosby, Inc. Terms and Conditions